Oura / Oura Health Oy

August 18, 2015. Oura — a four-person team in Oulu, Finland — opens its Kickstarter campaign with a $100,000 goal. The pitch: a finger-worn 'wellness computer' that tracks sleep, heart rate, and body temperature. Hits the goal in 15 hours.

The campaign runs 37 days. Closes September 24, 2015 with 2,383 backers and $651,803 in pledges — 6.5× the goal. Featured as a Kickstarter Staff Pick and listed as 'New & Noteworthy.'

Five months earlier, in March 2015, Oura had unveiled the Gen 1 ring at the San Francisco Launch Festival. Apple Watch had launched a few weeks before that, in April 2015. The wearable category was about to get loud — and Oura was making the contrarian bet that the wrist was the wrong location.

Why the Kickstarter outperformed

Three things were true about the 2015 wearable market that the founders read correctly:

• Sleep tracking was underserved. Fitbit dominated step-counting. Apple Watch was about to dominate notifications. Nobody was making a serious sleep-first device. Sleep is also when wrist-worn devices fail (uncomfortable to sleep in, motion artifact, daily charging interrupts wear).
• Quantified-self had hardened into a real subculture. The community had been growing since 2007 around the Quantified Self conferences. By 2015 there was a mid-five-figure population willing to pay $300+ for a measurement device with one specific job.
• Finland had brand credibility for sensor hardware. Polar (heart-rate monitors), Suunto (sport watches), Nokia. International backers already trusted that Oulu engineers could build precise sensors.

The campaign ran during the right month (August, when summer wellness content peaks) and pitched a specific use case (sleep, not 'health'). Narrow positioning + underserved use case = the formula behind almost every successful crowdfunding moment in hardware.

The two-year delivery problem

The pledged ring was supposed to ship in early 2016. Most backers received their rings 12-24 months later. Sensor-calibration issues, app integration problems, manufacturing yields — the standard hardware-startup graveyard.

Oura's response set a pattern that traveled forward:

• Frequent, transparent updates to backers explaining delays.
• No attempt to refund-out of the campaign.
• Eventually shipping a ring that worked — and inviting backers to upgrade to Gen 2 at favorable pricing.

The 2,383 original backers became the early product-feedback engine for Gen 2 (2017) and Gen 3 (2021). The 'Oura Insiders' community traces directly to that backer list.

What the $651K actually bought

The capital was small relative to what came later. The validation was massive. Three months after the Kickstarter closed, Oura raised a $2.3M seed round led by Lifeline Ventures. That seed almost certainly doesn't price the same way without 2,383 strangers having pre-paid.

Why this matters for hardware GTM

Software companies can launch quietly and iterate from zero usage. Hardware companies cannot — they need to know whether anyone will pay before tooling a single mold.

Kickstarter (and Indiegogo) compress that demand-validation step from years to weeks, and convert it into working capital instead of dilution. For consumer hardware between 2010 and 2018, the Kickstarter campaign was the GTM equivalent of seed-round product-market-fit signal.

What changed after 2018: Kickstarter became flooded with vapor projects, the platform's trust premium decayed, and the stigma of late delivery hardened. By the time Whoop or Levels launched (2014, 2018), they skipped Kickstarter entirely — the channel had stopped being a credibility-builder.

Oura caught the window when crowdfunding still earned credibility. Whoop and Levels did not.

Sources

• Oura Kickstarter campaign page
• Oura's history of the Kickstarter
• Quantified Self: Oura Ring on Kickstarter (2015)
• Geeky Gadgets: Oura Ring Wellness Computer Hits Kickstarter

June 23, 2020. The NBA, restarting its suspended season inside a sealed quarantine campus at Disney's Wide World of Sports complex in Orlando, announces a partnership with Oura. Every one of the ~350 players plus essential staff — coaches, trainers, media — is offered a titanium Oura Ring to wear for the duration of the bubble.

The ring's job: flag potential COVID symptoms via skin temperature, heart rate, and HRV, up to ~2.75 days before symptom onset. (The "90% predictive accuracy" figure widely circulated in 2020 marketing was later refined by UCSF's peer-reviewed TemPredict study, published in Scientific Reports in March 2022, to 82% sensitivity / 63% specificity at the 2.75-day window.) The deployment was optional. Most players opted in.

The story landed everywhere: NYT, ESPN, CBS Sports, CNBC, Sports Illustrated, Engadget, Fortune. Tens of millions of impressions, $0 in paid placement.

What was already in place — March 2020

Three things had to be true for the NBA partnership to happen at all. Each had been built years earlier:

1. UCSF TemPredict study (started March 25, 2020). A 63,153-participant study using Oura Rings to detect COVID early. The algorithm later showed 82% sensitivity at flagging COVID 2.75 days before symptoms. Oura wasn't speculating. It had research backing the claim.

2. Existing professional-sports adoption. A handful of NBA, NFL, and Olympic athletes were already wearing Oura privately by 2019. Word had spread inside locker rooms. The NBA didn't pick a random ring — it picked the one its players already trusted.

3. The ring's form factor fit the use case. A Whoop strap or Apple Watch couldn't survive a basketball game (Apple Watch needs nightly charging, Whoop bulk interferes with shooting). The Oura Ring fit unobtrusively. Form factor met moment.

The day-by-day press wave

Three months between the NBA announcement and the cascade of follow-on partnerships. Each one cited the NBA deployment as precedent. The first credible institutional customer underwrote every subsequent one.

Why it worked at the brand level

Three structural reasons the moment landed:

• Athletes are aspirational fitness identities. A ring on LeBron James's finger is a different signal than a ring in a wellness blogger's Instagram post. Sports broadcasts also forced the ring into casual TV viewers' eyeline — the largest possible audience.
• COVID context made the ring's claim immediately relevant. Pre-COVID, "tracks your sleep" is a niche feature. During COVID, "warns you 2.75 days before symptoms" is a public-health utility. The pitch slot widened by a factor of 100.
• The ring's discreet form was the visual hook. Pundits asked "what's that ring?" because it didn't look like a fitness device. Mystery drove search volume — Google Trends for "Oura Ring" stepped up sharply in the week after the NBA announcement.

The NBA bubble is the single inflection that converted seven years of product credibility into mainstream brand awareness in one news cycle. The work that came before made Oura a candidate for the role; the role itself made it a household name.

What the NBA deployment did NOT do

Two things people often credit it with that aren't actually true:

• It didn't drive immediate hardware sales. Oura's Series B closed in March 2020 (pre-NBA) at ~$200M valuation and 150K lifetime rings. The 1M-rings milestone wasn't until March 2022 — almost two years later. The bubble didn't compress hardware sales; it compressed brand-awareness years.
• It didn't make the company profitable. Profitability didn't arrive until 2024, after the Gen 3 subscription pivot reset the unit economics. Brand awareness is upstream of revenue, not the same thing.

What it did do: pre-position Oura as the credible health-research wearable. The Department of Defense pilot (2019, expanded post-NBA), the UFC deal, the celebrity wave — Jennifer Aniston, Prince Harry, Jack Dorsey — all came downstream of the NBA bubble being the public-record reference.

The luck question

Was this lucky? Yes — the pandemic made it possible. Was it coincidence? No — Oura had spent six years preparing the ground.

The right framing: a black-swan opportunity met a company that was prepared for it. UCSF was running a study. Pro athletes were already wearing rings. The form factor was correct. The sensor stack was credible. The PR team picked up the phone when the NBA called.

A different smart-ring company in 2020 could not have taken this opportunity. Oura was the only one ready.

Sources

• Oura partnership announcement
• CNBC: Inside the NBA's plan to use smart technology
• Sports Illustrated: Why the Oura ring is key
• TemPredict study (Nature Scientific Reports)
• Engadget: NBA restart plan

October 26, 2021. Oura launches the third-generation ring. Hardware price: $299, the same as Gen 2. Major sensor upgrades — 24/7 heart rate, blood oxygen via SpO2, period prediction, skin temperature trends.

Then the catch: most features now require a $5.99/month membership ($69.99/year). Existing Gen 2 owners keep their full feature set. Gen 3 buyers get one month free, then pay.

User reaction was immediate. The r/ouraring subreddit lit up. TechCrunch's Gen 3 review was titled "Bling Ring's Price Stings." The Tech Advisor headline: "embarrassingly limited" without subscription. Wired, The Verge, Tom's Guide all led with the subscription as the primary critique.

The pre-pivot economics problem

To understand why Oura did this, look at the unit economics before October 2021.

This is the Fitbit problem. Hardware companies live on a single transaction. Once you've sold someone the device, the software cost (cloud, app development, data science, customer support) keeps running — but the revenue doesn't.

Fitbit's gross margins compressed every year as the category matured. By 2019, Fitbit was struggling to stay profitable, and Google acquired it for $2.1B — a 50% discount to its 2015 IPO valuation. The market knew where pure-hardware fitness companies ended up.

Oura's leadership read the same data. Harpreet Rai (then CEO) and the board had a choice: stay pure hardware and accept the multiples, or break the social contract with the install base and become a software company.

The post-pivot economics

A year of subscription, on top of the $299 hardware:

The subscription is incremental margin, not cannibalized hardware revenue. Across the 1.3M rings sold in 2024, that's roughly $144M in additional annual subscription revenue at software margins, on top of $390M in hardware revenue.

The mix matters: by 2024, software was ~30% of revenue but a much larger share of gross profit. That mix is what justified the $11B Series E valuation in October 2025 — public-market hardware peers like GoPro and Fitbit traded at 1-2x revenue. Oura traded at 11x revenue.

The backlash math — and why it didn't kill the company

Three reasons the membership controversy didn't tank sales:

• Existing Gen 2 owners stayed grandfathered. The most loud users on Reddit and Twitter weren't actually paying the new fee — they had legacy access. Their criticism was vocal but their revenue was preserved.
• New buyers self-selected with eyes open. Anyone buying a Gen 3 in November 2021 onward knew about the subscription. The backlash filtered out the price-sensitive segment, leaving the segment that converted to paid at very high rates.
• The pricing was anchored against the right comparison. $5.99/month is less than Spotify, less than Netflix, less than most VPNs. Compared to other consumer subscriptions, Oura looked reasonable. Compared to "free, like before," it looked greedy. Oura controlled the comparison set in its launch communications.

By March 2022 — five months after Gen 3 launched — Oura crossed 1 million lifetime rings sold, with Gen 3 outselling all prior generations combined. The subscription didn't deter buyers. It compressed which buyers came through.

The Reddit response

r/ouraring captured the user-revolt narrative. Top threads in November 2021 — "Subscription is unacceptable," "Switching to Whoop," "Cancel my pre-order." Hundreds of comments, mostly negative.

Six months later, the same subreddit was discussing readiness scores, sleep efficiency, and HRV trends — the actual user behavior was unaffected. The forum hottest about a price change is rarely the forum that stops paying. The marginal buyer who walked was usually someone who wasn't going to be a long-term user anyway.

Oura's leadership read this dynamic correctly. They didn't reverse the policy. They didn't apologize. They kept Gen 2 owners grandfathered, communicated the value of the subscription clearly, and let time prove the unit economics.

The Tom Hale link

The subscription pivot launched in October 2021 under CEO Harpreet Rai. Six months later, in April 2022, Rai was out and Tom Hale — former president of SurveyMonkey/Momentive — was in.

The timing isn't a coincidence. The pivot from hardware to subscription required a software-CEO mindset to scale. Hale's prior 30 years had been in subscription consumer software (Adobe/Macromedia, HomeAway, Momentive). He was the right operator for the post-subscription Oura.

Whether Rai resigned voluntarily or was eased out is unclear from public records. What's clear: the company that needed leading after October 2021 wasn't the company Rai had been hired to lead.

Sources

• Oura Gen 3 launch announcement
• TechCrunch: Oura Ring 3 review
• Tech Advisor: Bling Ring's Price Stings
• Wikipedia: Oura Health subscription details
• WebProNews: Oura's subscription gamble

April 25, 2022. Oura announces Tom Hale as CEO. The Bloomberg headline: "Oura Ring Startup Brings on New CEO to Lead Its Pre-IPO Growth Push." Hale starts the same day. COO Michael Chapp, who had been interim CEO since Harpreet Rai's December 2021 departure, returns to operations.

Hale's prior 30 years: Adobe/Macromedia, HomeAway, then president of Momentive (the holding company that owns SurveyMonkey). Momentive went public in 2018 under his commercial leadership. None of Hale's prior companies made hardware.

That was the point.

The three CEO eras

Oura has had three distinct leadership profiles, each matching a phase:

Lahtela was the right founder-CEO for the build years. Rai (former Eminence Capital portfolio manager) was the right investor-mindset CEO for the commercial scaling. Hale was the right software-operator CEO for the post-subscription platform years. Three phases, three different operating profiles, three different leadership profiles.

This kind of clean handoff is rare. Most founder-led companies hold on too long. Most VC-installed CEOs miss the next phase shift. Oura's board (Lifeline Ventures, Forerunner, Chernin Group) executed two transitions cleanly.

What changed under Hale

The four years following Hale's appointment compressed more strategic moves than the first nine years combined:

Three patterns visible:

• Bundled announcements. The Series D was paired with Dexcom's $75M and the partnership reveal. The Series E was paired with the 5.5M-rings milestone. Hale's communications discipline is to never let a single announcement fire alone.
• Strategic acquisitions over organic build. Proxy (digital identity), Veri (CGM software), Sparta Science (B2B movement health). All three filled platform gaps that organic R&D would have taken 2-3 years to deliver.
• Distribution expansion before product expansion. Retail (Best Buy 2023, Target 2024) and enterprise (DoD, Oura Teams) came before the next major product generation. Channel breadth scales the existing product before the next product needs to scale.

This is software-platform playbook applied to hardware. Acquire to fill gaps. Distribute to compound install base. Bundle announcements for compounded coverage. It's Hale's prior playbook from the Momentive years, transferred.

The pre-IPO framing

The Bloomberg headline announcing Hale's hire — "Pre-IPO Growth Push" — was the public signal. By 2022, Oura's investor mix included Forerunner, Chernin, Temasek, Square, MSD Capital. The capital base was IPO-grade.

But four years later, Oura is still private. The Series E ($900M at $11B) in October 2025 effectively delays IPO timing. A round that large at that valuation, from public-market-style investors like Fidelity and ICONIQ, gives the company runway to stay private well into 2027 or later.

Why delay? Three plausible reasons:

• Hardware multiples ambiguity. Public markets have priced consumer hardware companies (GoPro, Fitbit, Peloton, Roku) brutally over the past five years. Oura wants more software-mix proof before it tests that pricing.
• Glucose roadmap unfinished. The Dexcom partnership's first integration shipped H1 2025. The deeper metabolic-health platform is still being built. IPOing before that lever is mature would underprice the platform.
• AI Advisor's commercial impact unclear. Oura Advisor went GA in March 2025. Whether it drives subscription retention or upsell is still being measured. IPOing before that data is in is a valuation risk.

Hale's job in 2026-2027 is to land all three of those before the IPO window opens. The four-year-and-counting "pre-IPO push" has become an extended platform-build, not a sprint.

What didn't change

Two things Hale visibly preserved:

• The Finnish R&D center. Hale moved Oura's commercial center of gravity to San Francisco but kept the engineering core in Oulu and Helsinki. The hardware quality and sensor IP that defined Oura wasn't outsourced.
• The subscription model. Despite the launch backlash, Hale didn't reverse Gen 3's $5.99/month policy. He doubled down — kept it for Ring 4, built Oura Advisor on top of it, and let it become the foundation of the platform thesis.

The continuity matters. Hale's job wasn't to redirect the company. It was to scale the strategic decisions Rai had already made. That's a different mandate from a turnaround CEO, and Oura's board picked correctly for the mandate.

Sources

• Bloomberg: Oura Ring Startup Brings on New CEO
• TechCrunch: Oura's new CEO discusses the future of the smart ring
• Oura blog: Tom Hale joins as CEO
• Mobi Health News: Oura taps Tom Hale as CEO

May 26, 2022. Oura and Gucci launch a limited-edition collaboration ring. Retail price: $950 — three times the price of a standard Gen 3.

The hardware is Oura Gen 3 internals. The exterior is Gucci-signature: black PVD-coated titanium with a subtle interlocking-G monogram and an 18-karat yellow gold braided torchon along the outside band. Sold on Gucci.com and Oura.com plus select Gucci retail locations worldwide. Includes lifetime Oura membership (a separate $71.88/year value).

Sells out within weeks. Returns for a limited-edition rerun in 2023.

What this was actually about

Three things the partnership was not about:

• Volume. A few thousand $950 rings is rounding error against Oura's million-plus annual unit volume.
• Margin. Co-branding splits typically share margin with the partner; the gold detailing also adds material cost. The unit economics on this SKU are weaker than the standard Gen 3.
• Gucci's customer base buying Oura. Most Gucci customers aren't in the market for a sleep tracker. The Venn overlap is real but small.

What it was actually about: the brand category Oura sat in.

Pre-2022 Oura was filed under "fitness wearable / health tech" alongside Whoop, Fitbit, Garmin, and Apple Watch. Post-Gucci, the category framing widened to include luxury wellness — Hermès Apple Watch bands, Cartier rings, Tag Heuer Connected. A different shelf, a different price tolerance, and a different demographic.

The press coverage that mattered

The collaboration ran in publications that don't normally cover wearables:

Compare that to the press surfaces TechCrunch and CNBC reach. Different readership, different positioning carry. A WWD feature on Oura signals to the fashion buying community that the ring belongs in their consideration set.

The cost of accessing those press surfaces directly via paid placement would have been hundreds of thousands of dollars. The Gucci collaboration delivered them for the cost of a co-branding deal.

Why Gucci said yes

Gucci wasn't doing Oura a favor. The partnership made strategic sense for both sides:

• Gucci was building Gucci Vault — a digital-first concept store featuring younger and more experimental partnerships. Oura fit that brief.
• Wellness was rising as a luxury category. By 2022, $5,000 cold plunges, $2,000 saunas, and $300/month Erewhon smoothies were normalized. A $950 health ring was on-trend.
• Tech-enabled luxury was a thesis. Apple Watch + Hermès had proved consumers would pay 2-3x for fashion-coded wearables. Gucci needed a competitive answer.

The partnership benefited from Gucci CEO Marco Bizzarri's open stance toward tech-fashion crossovers — a stance that softened after Bizzarri's departure in 2023 and the broader luxury-market correction in 2024.

The female-demographic angle

A second-order effect of the Gucci collaboration: it accelerated Oura's pivot toward female consumers.

Pre-2022, Oura's user base skewed male and Silicon Valley — biohackers, optimization-curious tech workers, professional athletes. Gucci x Oura broke that frame. The fashion press coverage skewed female. The retail point of sale (Gucci stores) skewed female-affluent. The aesthetic frame (gold detailing, jewelry-coded design) skewed female.

By 2024, Oura disclosed that female shoppers were its fastest-growing demographic. The Target distribution launch (April 2024) was explicitly designed around that pivot. The Gucci collaboration was the leading-edge signal that this shift was already underway.

The luxury-wellness flywheel

The Gucci ring also unlocked a positioning Oura kept exploiting:

• 2022: Gucci x Oura collaboration
• 2023: Best Buy retail launch with dedicated 11×11 store-within-stores
• 2024: Target distribution opens
• 2024: Ring 4 launches with full-titanium interior, sleeker design
• 2025: Gold/silver finishes positioned as everyday-wear jewelry

Each step compounded the same brand framing: Oura is jewelry that happens to track your health, not a fitness device that happens to be on your finger. The Gucci moment was the one that made that framing credible to the broader fashion ecosystem.

What Whoop and Apple did NOT do

Whoop, by 2022, had a $3.6B valuation and a clear positioning — serious athletes, performance optimization. Whoop never did a luxury-fashion collaboration. The brand stayed in the gym.

Apple Watch had Hermès bands from 2015 onward — but the Hermès collaboration is interchangeable with the standard watch. The watch itself is the same; only the band is different. Gucci x Oura was an actual co-designed product. The integration was deeper.

The competitive lesson: a one-time fashion collaboration is a positioning move, not a product line. Whoop's discipline of staying in-lane is also valid; Oura's audience-broadening move worked because Oura had a discreet form factor that could carry the fashion frame. Whoop's chest strap cannot.

Sources

• Oura: Introducing Gucci x Oura
• TechCrunch: Gucci x Oura launch a $950 smart ring
• Hypebeast: Oura and Gucci craft an 18-Carat Gold Smart Ring
• WWD: Gucci x Oura Ring
• Highsnobiety: Gucci & Oura's $950 Ring

October 3, 2024. Oura announces the Ring 4. Hardware price: $349. Ships October 15, 2024. Subscription unchanged at $5.99/mo or $69.99/yr.

The headline upgrades:

• Smart Sensing: New algorithms compensate for the ring's natural rotation on the finger. Sensors are now flat (not raised), so the ring twists 30° in either direction without losing signal. Per Oura's data, this delivered "big boosts" in blood-oxygen accuracy and reduced gaps in heart-rate tracking.
• Battery: Up to 8 days (vs. 7 on Gen 3).
• Form factor: Twelve sizes (up from eight), six colors. All finishes fully titanium for the first time — no plastic interior.
• Workout detection: 40+ activity types automatically recognized (up from a handful).

Crucially, Oura was no longer the only smart ring on US shelves. Samsung Galaxy Ring had shipped in the US three months earlier — July 24, 2024, at $399 — meaning Ring 4 launched into a competitive market for the first time in Oura's history.

The competitive frame Ring 4 entered

By October 2024, the smart-ring market had fundamentally changed:

For the first time, Oura had real competition with comparable form factors. Samsung in particular brought what Oura couldn't: massive Android distribution, native Galaxy ecosystem integration, and no required subscription.

The form-factor bet, restated

Ring 4 doubled down on a single thesis: the ring form factor is the right answer for sleep and 24/7 wear. The competition was about to test that thesis at the highest stakes yet.

Three structural reasons Oura kept (and arguably strengthened) the lead despite Samsung's entry:

• Battery life. Apple Watch lasts 18-36 hours. Samsung Galaxy Ring lasts ~7 days. Oura Ring 4 lasts 8 days. The ring's battery advantage is structural — smaller surface area means smaller display means lower power draw means longer life. Apple cannot solve this without redesigning the watch from scratch.
• Sleep tracking accuracy. Finger-PPG produces cleaner signals than wrist-PPG due to less motion artifact. Multiple peer-reviewed studies validate this — the form-factor bet from 2014 paid off in measurable accuracy advantages a decade later.
• Aesthetic. Oura looks like jewelry. Samsung Galaxy Ring (so far) looks like a smaller smart watch on your finger. The fashion frame Gucci helped Oura earn doesn't transfer to Samsung.

What the Ring 4 launch did NOT change

Three things conspicuously absent from the Ring 4 launch:

• No price decrease. Despite Ultrahuman undercutting at sub-$300 with no subscription, Oura held $349 + subscription. The signal: Oura is positioning as premium, not as the value option.
• No major feature additions visible to existing Gen 3 owners. The upgrades are sensor accuracy and form factor. There's no killer feature that forces Gen 3 owners to upgrade — by design. Hardware refresh, not software step-change.
• No glucose integration at launch. The Dexcom partnership announced six weeks later (November 19, 2024) was the bigger software story. Ring 4 was hardware-positioned; the software platform story was held for separate disclosure. Bundling discipline preserved.

The October 2024 quarter as Hale's defining month

Look at what shipped in roughly four weeks:

Six major announcements in 11 weeks. Each one positioned for a specific audience:

• Ring 4 → consumer press
• DoD contract → defense + government press
• Sparta Science → B2B health press
• Dexcom partnership → medtech + capital press
• Series D → financial press

This is the Hale playbook at its most disciplined. One quarter of bundled announcements that compressed 18 months of strategic narrative into a single news cycle. The Series D valuation step-up (2.55B → 5.2B = +105%) reflected the cumulative weight of all six announcements, not just the funding event.

The Samsung Galaxy Ring stress test

Samsung Galaxy Ring shipped in the US in late 2024 / early 2025. By Q1 2025, retail data showed:

• Oura's market share dropped from ~80% to ~70% globally.
• Samsung captured the bulk of the new entrants — primarily Android-first users who valued ecosystem integration over Oura's depth.
• Oura's revenue continued doubling YoY, suggesting Samsung was expanding the category rather than cannibalizing Oura directly.

The category got bigger, Oura's slice got smaller, but Oura's absolute volume kept growing. Hale's framing in subsequent CNBC interviews: "Samsung validates the category. We win because we're better."

This is the right framing. Samsung's entry confirms that smart rings aren't a niche — and Oura's competitive moat (subscription data flywheel, sensor accuracy, brand) holds up better when the category itself is growing.

Sources

• CNBC: Oura Ring 4 announced for $349
• Oura: Discover the Brand-New Oura Ring 4
• Tom's Guide: Oura Ring 4 review — the new gold standard
• TechRadar: Oura Ring 4 features and specs
• Tom's Guide: Samsung Galaxy Ring vs Oura Ring 4

November 19, 2024. Dexcom — the public-market leader in continuous glucose monitoring (NASDAQ: DXCM, market cap ~$30B at the time) — announces a strategic $75M investment in Oura. Folded into Oura's Series D. The two companies will integrate data between Dexcom's CGM patches and the Oura Ring app, plus co-market and cross-sell each other's products.

The valuation Oura discloses simultaneously: $5.2B. More than double its 2022 valuation in 31 months.

The first integration ships H1 2025. By March 2025, glucose data flows from Dexcom's Stelo (the over-the-counter CGM Dexcom launched in August 2024) into the Oura app alongside sleep, HRV, stress, and activity data.

Why glucose is the next wedge

Continuous glucose monitoring has been medical-only for two decades — patches you wear for two weeks that show your blood-glucose curve in real time. Until 2024, you needed a prescription.

Three things changed in 2024:

• Dexcom Stelo launched OTC in August 2024. No prescription. $89/month. The first FDA-cleared OTC continuous glucose monitor.
• Abbott Lingo (also OTC, August 2024) entered the same category. A direct competitor signaled that the consumer CGM market was real.
• Levels, NutriSense, and Veri had spent the prior three years building consumer apps on top of medical-grade CGMs. The category was already proven at the application layer.

The bet: glucose is the next sleep. A continuous, daily, ongoing biometric signal that consumers want to optimize, that has clear behavioral feedback (food → spike → fatigue), and that no wrist-worn device can capture today.

Oura's existing data stack — sleep, HRV, temperature, stress, activity — already explains recovery and readiness. Add glucose, and you have a complete metabolic-health picture. The two halves combine into a category neither company can offer alone.

What Dexcom gets

Dexcom's strategic logic for partnering with Oura, not buying it outright:

• Distribution into a younger, healthier demographic. Dexcom's existing user base skews diabetic and 50+. Oura's user base skews 25-45 wellness-curious. The cross-sell potential is large.
• Lifestyle context Dexcom alone can't deliver. A glucose spike at 3pm is just data. A glucose spike at 3pm correlated with poor sleep the night before, low HRV, and a high-stress workout that morning is a behavioral story. Oura provides the context.
• Avoiding the smart ring market directly. Building a ring would take Dexcom 3-5 years and cost hundreds of millions, with no guarantee of competing with Oura's 80% market share. Better to partner with the leader and split the metabolic-health market.

Dexcom has also been blunted by Abbott's Lingo and the rise of consumer CGM startups. The Oura partnership is part defensive — a moat-building move that signals Dexcom is the metabolic-health platform Apple Health, Whoop, and Apple Watch will eventually have to plug into.

What Oura gets

Three concrete benefits:

• A category-defining strategic partner. Dexcom is the public-market name for CGM. Co-marketing legitimizes Oura as the metabolic-health partner of choice — over Whoop, Apple Watch, or Samsung Galaxy Ring.
• The Veri acquisition (Sep 2024) finally has a hardware partner. Veri's CGM software was running on third-party patches before. Now it has Dexcom's roadmap and supply chain.
• A $5B valuation anchor. The Series D valuation post-Dexcom was a 105% step-up from 2022's $2.55B. Strategic investors price differently from financial investors. Dexcom putting $75M in is a different signal than Fidelity putting $125M in.

The bundling discipline

The Dexcom deal demonstrates Oura's announcement discipline. The November 19 news bundle:

Six headlines, one news cycle, multiple press surfaces. TechCrunch, MedTech Dive, Fierce Healthcare, MobiHealth News, MedicalDevice-Network, WWD, CNBC. Each angle reaches a different audience.

Tom Hale's communications instinct: never let a single announcement fire alone. The Dexcom deal was four months before the Series D would have closed financially anyway. Bundling them into one announcement compressed the press coverage into a single cycle instead of two.

The 2025 follow-through

What happened in the 12 months after the announcement:

• March 2025: Oura Advisor (AI) goes GA — built to interpret the combined biometric data including glucose.
• May 2025: Oura announces Meals + Glucose features powered by AI.
• September 2025: 5.5M rings sold disclosed; revenue tracking past $1B.
• October 2025: Series E at $11B — partly justified by the metabolic-health platform now being real, not theoretical.

The Series E re-pricing (5.2B → 11B in 10 months) reflects the market accepting the platform thesis. Glucose was the proof point.

Risks to the thesis

Three things could undermine the bet:

• Stelo and Lingo commodify CGM faster than expected. If glucose monitoring becomes a $20/month commodity, the strategic premium disappears.
• Apple or Samsung introduces non-invasive glucose sensing. Both are reportedly pursuing optical glucose monitoring. If a wrist-worn device can do glucose without patches, the Dexcom partnership loses some of its moat.
• Consumers don't want metabolic context. The Levels and NutriSense user-research data so far suggests strong interest, but the category is small. If glucose stays niche, the platform becomes incremental rather than transformative.

None of these have hit yet. Oura's bet has 2-3 years to play out before any of them matter at the valuation level.

Sources

• TechCrunch: Oura valued at $5B following deal with Dexcom
• Dexcom press release on the partnership
• Fierce Healthcare: Dexcom invests $75M in Oura
• MedTech Dive: Dexcom invests $75M, integrates smart rings and CGMs
• WWD: Oura Series D + Dexcom partnership

October 14, 2025. Oura announces a $900M Series E led by Fidelity Management & Research Company, with new investors ICONIQ Capital, Whale Rock, and Atreides. Valuation: $11 billion.

The previous round — Series D at $5.2B — had closed 10 months earlier. Valuation step-up: 2.1x in under a year.

Tom Hale tells CNBC the same week: 2025 revenue tracking to ~$1B, and 2026 revenue expected to approach $2B. Implied 2025 revenue multiple: 11x. Implied 2026 forward multiple: ~5.5x.

For context, public-market hardware peers trade at very different multiples:

Oura is being priced as a software company, not a hardware company. The 11x revenue multiple is what enterprise SaaS earns at scale — Datadog, MongoDB, ServiceNow. Hardware companies don't get that ratio. So what convinced Fidelity to underwrite Oura at software multiples?

The four-year bridge to platform pricing

Look at the cumulative evidence Oura built between Hale's appointment (April 2022) and the Series E (October 2025):

Subscription proof.

• 2 million paying subscribers by late 2024
• ~$144M annualized subscription revenue
• 30% of revenue, ~50% of gross profit (estimated)

Distribution scale.

• Best Buy (April 2023)
• Target (April 2024)
• US-based defense manufacturing (announced 2024)
• 5.5M rings sold lifetime by September 2025

Platform expansion.

• Proxy (May 2023) — digital identity
• Veri (Sep 2024) — metabolic health software
• Sparta Science (Oct 2024) — B2B movement health
• Dexcom partnership (Nov 2024) — CGM data integration

AI layer.

• Oura Advisor beta (July 2024)
• Oura Advisor GA (March 2025)
• Meals + Glucose AI features (May 2025)

Enterprise + government.

• DoD partnership since 2019
• $96M Department of Defense contract (Oct 2024)
• Oura Teams B2B offering scaled

By October 2025, Oura had passed every gate that separates a hardware company from a platform company. Recurring revenue. Multi-product surface. Strategic partnerships with public-market leaders. Enterprise channel. AI layer. Brand category-leadership.

Fidelity didn't underwrite a wearable. It underwrote a platform.

The bundling discipline, perfected

The Series E announcement bundled six data points into one news cycle:

Six headlines, one news cycle. Each press surface gets a different angle. Each angle compounds the others. This is the Hale-era communications discipline at maximum execution.

What the Series E says about an IPO

Three things the size and composition of this round signal:

• Public-market readiness check, not IPO trigger. Fidelity, ICONIQ, Whale Rock, and Atreides are all public-market investors who buy late-stage privates as IPO-window stand-ins. Their participation is the public market saying: "We'd buy this. Wait until 2027 to list it."
• No urgency for liquidity. $900M of fresh capital plus existing reserves means Oura can stay private into 2027 and beyond. The earlier "pre-IPO" framing under Hale's 2022 hire has expanded into a multi-year pre-IPO operating period.
• Glucose roadmap and AI layer need more time. The Dexcom integration shipped H1 2025. AI Advisor went GA in March 2025. Both are early. Hale's likely calculus: don't IPO until both are mature commercial drivers, because a public market that prices them as mature will pay more than one that prices them as bets.

The 2026 question

Hale's CNBC guidance: ~$2B in 2026 revenue. If achieved, that compresses the forward revenue multiple from 11x (TTM) to ~5.5x (forward). At 5.5x, Oura is closer to Garmin's multiple than Datadog's — still premium for hardware, but defensible.

Three things have to be true for the $2B number to land:

• Doubling continues. Oura has doubled YoY in 2023 (~$227M → $500M) and 2024 ($500M → ~$1B). Doubling from $1B to $2B is harder. Most companies that double from $500M to $1B fail to repeat.
• International expansion compounds. US revenue is the bulk today. Europe, Japan, and Southeast Asia are early. Geographic expansion is the cleanest near-term lever.
• Subscription retention holds. Net revenue retention (NRR) on the $5.99/month tier is the silent variable. If churn is high, the $2B number requires unsustainable hardware velocity.

If 2026 lands, the IPO window opens cleanly in 2027 at $20-25B+. If it misses, the Series E becomes the high-water mark and the next funding event is a flat or down round.

What's still ambiguous

Public records don't show:

• Net revenue retention. Critical for the platform thesis. Not disclosed.
• Hardware vs subscription unit economics by SKU. Ring 4 vs Ring 3 sell-through, Gucci edition margins, defense margins — none disclosed.
• Geographic mix. US dominance assumed; international acceleration unclear.
• AI Advisor commercial impact. Early usage data positive, but conversion to subscription retention or upsell unproven.

These are exactly the metrics an S-1 would have to disclose. Whether Oura discloses them via S-1 in 2027 or in a continued series of partial disclosures via Hale's press interviews will be one of the more interesting communications-strategy questions of the next 18 months.

Sources

• TechCrunch: Smart ring maker Oura raises $900M from Fidelity
• CNBC: Oura reaches $11 billion valuation with new $900 million fundraise
• BusinessWire: Oura raises over $900M
• Fierce Healthcare: Oura raises $900M Series E
• Forerunner Ventures: From Ring to Revolution
• CNBC: Oura expects close to $2B in 2026 sales